Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM83WVF)

• Drug Name: Apicidin Drug Info
• Synonyms: CHEMBL430060; OSI-2040; (3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone; Acipidin; AC1OCFAM; Apicidin _120249; SCHEMBL147997; ChEMBL_275631; GTPL7495; DTXSID40274182; MolPort-005-944-562; BDBM50238632; ZINC17654900; AKOS030622920; MCULE-8969470747; NCGC00165733-01

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6918328
  TTD Drug ID: DM83WVF

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[7]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[8]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[9]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[10]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[11]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[12]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[9]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[13]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[14]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[15]

Drug(s) Affected By Transcription factor E2F8 (E2F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[19]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[20]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[24]

Drug(s) Affected By Huntingtin-interacting protein 1 (HIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[18]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[29]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]

Drug(s) Affected By SLIT-ROBO Rho GTPase-activating protein 3 (SRGAP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[36]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[39]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[37]

Drug(s) Affected By Dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[44]

Drug(s) Affected By A-kinase anchor protein 8 (AKAP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[45]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[46]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[45]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[48]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[49]

Drug(s) Affected By Transmembrane and coiled-coil domains protein 2 (TMCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[50]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[51]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[52]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[53]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[54]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[55]

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[56]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[57]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[58]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[60]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[61]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[59]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[64]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[65]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[68]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[69]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[70]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[71]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[72]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[73]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[74]

Drug(s) Affected By Myb-related protein A (MYBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[75]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[77]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[76]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[80]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[81]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[82]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[83]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[84]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[86]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[87]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[88]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[89]

Drug(s) Affected By Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[90]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[91]
Selenium	DM25CGV	N. A.	N. A.	Approved	[92]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[93]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[95]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[98]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]

Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[99]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[101]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[92]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[103]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[104]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[105]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[106]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]

Drug(s) Affected By Guanine nucleotide-binding protein G(z) subunit alpha (GNAZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[107]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[102]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[108]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[109]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[110]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]

Drug(s) Affected By Cyclin-A2 (CCNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[111]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[112]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[114]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[115]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[116]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[117]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]

Drug(s) Affected By Glycine dehydrogenase (GLDC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[18]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[119]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[120]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[121]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[122]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[89]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[57]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[123]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[124]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[125]
Selenium	DM25CGV	N. A.	N. A.	Approved	[110]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[126]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[127]

Drug(s) Affected By G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[128]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[114]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[104]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[115]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[129]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[130]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[132]

Drug(s) Affected By Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[99]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[128]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[133]
Selenium	DM25CGV	N. A.	N. A.	Approved	[92]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[104]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[134]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[135]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[95]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 6 (FAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[136]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[137]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[138]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[139]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[140]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[141]
Fructose	DM43AN2	Vomiting	MD90	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[136]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[143]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[144]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[145]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[101]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[146]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[124]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[103]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[147]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[104]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[148]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[149]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[150]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[151]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[69]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[152]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[153]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[154]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[155]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[156]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[157]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[158]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[123]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[147]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[159]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[160]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[161]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[129]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[162]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[163]

Drug(s) Affected By Max-interacting protein 1 (MXI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[165]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[165]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[166]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[167]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[168]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[87]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[169]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[170]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[137]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[171]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[172]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[173]

Drug(s) Affected By Caspase-6 (CASP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[174]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[176]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[177]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[178]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[179]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[174]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[180]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[181]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[169]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[182]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[183]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[184]
Pefloxacin	DM49IGF	Gonococcal urethritis	1A70.0Y	Approved	[185]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[80]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[157]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[86]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[136]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[169]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[124]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[187]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[104]

Drug(s) Affected By Serine/arginine-rich splicing factor 4 (SRSF4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[188]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[188]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[189]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[190]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[48]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[191]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[55]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[49]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[49]

Drug(s) Affected By Zinc transporter ZIP6 (SLC39A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[192]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[193]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Gallium nitrate	DMF9O6B	Hypercalcaemia	5B91.0	Approved	[195]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[196]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[192]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]

Drug(s) Affected By Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[197]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[198]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[199]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[198]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[200]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[201]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]

Drug(s) Affected By Enhancer of filamentation 1 (NEDD9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[202]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[202]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[165]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[165]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[165]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[203]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[204]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[205]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[174]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[206]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[207]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[137]
Selenium	DM25CGV	N. A.	N. A.	Approved	[110]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[172]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]

Drug(s) Affected By Cyclin-dependent kinase 5 activator 1 (CDK5R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[208]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[209]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[211]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[212]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[211]

Drug(s) Affected By Cytoplasmic polyadenylation element-binding protein 4 (CPEB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[213]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[214]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[215]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[216]

Drug(s) Affected By Male-specific lethal 1 homolog (MSL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[44]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[217]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[55]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[49]
Scriptaid	DM9JZ21	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[218]

Drug(s) Affected By 7SK snRNA methylphosphate capping enzyme (MEPCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[3]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[45]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[109]

Drug(s) Affected By TBC1 domain family member 16 (TBC1D16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[219]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[36]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[212]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[216]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]

Drug(s) Affected By Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[220]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[221]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[222]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[223]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[224]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[225]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[226]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[227]
Mestranol	DMG3F94	Contraception	QA21	Approved	[228]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[229]

Drug(s) Affected By ELL-associated factor 2 (EAF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[230]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[231]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[166]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[50]

Drug(s) Affected By Small integral membrane protein 14 (SMIM14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[33]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[166]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]

Drug(s) Affected By PH and SEC7 domain-containing protein 3 (PSD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[232]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[233]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[234]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[235]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[43]

Drug(s) Affected By Tropomodulin-2 (TMOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[193]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[236]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[55]
Oxamflatin	DM1TG3C	Solid tumour/cancer	2A00-2F9Z	Terminated	[3]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[237]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[238]

Drug(s) Affected By Solute carrier family 12 member 6 (SLC12A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[49]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[239]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[47]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[241]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[109]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[242]

Drug(s) Affected By Two pore channel protein 1 (TPCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[165]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[165]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[165]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[243]

Drug(s) Affected By RING finger protein 24 (RNF24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[244]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[44]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[245]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[196]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase-like 1 (PPIL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[246]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[102]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[247]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[109]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[248]

Drug(s) Affected By DmX-like protein 1 (DMXL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[249]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[249]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[233]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[250]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[234]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[251]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[252]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[253]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[254]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[255]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[256]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[257]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[258]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[259]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[257]

Drug(s) Affected By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[260]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[261]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[262]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[263]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[264]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[265]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[266]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[267]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[268]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[268]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
7SK snRNA methylphosphate capping enzyme (MEPCE)	OTRBQEYP	MEPCE_HUMAN	Gene/Protein Processing	[3]
A-kinase anchor protein 8 (AKAP8)	OTK3EQAI	AKAP8_HUMAN	Gene/Protein Processing	[3]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[4]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[4]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[5]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[4]
Caspase-6 (CASP6)	OTXLD3EC	CASP6_HUMAN	Gene/Protein Processing	[4]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[6]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[4]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7495).
• [2] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [3] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [4] Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem Biol Interact. 2008 Apr 15;172(3):235-44. doi: 10.1016/j.cbi.2008.01.007. Epub 2008 Feb 1.
• [5] Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer. 2006 Jan 1;118(1):90-7. doi: 10.1002/ijc.21297.
• [6] Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact. 2009 May 15;179(2-3):169-77. doi: 10.1016/j.cbi.2008.11.011. Epub 2008 Nov 25.
• [7] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [8] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [12] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [13] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [14] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [15] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [16] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [17] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [18] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [19] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [20] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [21] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [22] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [23] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [24] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [25] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [26] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [27] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [28] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [29] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [30] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [31] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [32] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [33] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [34] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [35] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [36] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [37] Influence of resveratrol on rheumatoid fibroblast-like synoviocytes analysed with gene chip transcription. Phytomedicine. 2013 Feb 15;20(3-4):310-8. doi: 10.1016/j.phymed.2012.09.020. Epub 2012 Nov 6.
• [38] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [39] Research resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant. Mol Endocrinol. 2014 Dec;28(12):2072-81.
• [40] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [41] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [42] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [43] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [44] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [45] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [46] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [47] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [48] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [49] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [50] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [51] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [52] Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer. 2008;60(3):382-8.
• [53] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [54] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [55] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [56] Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
• [57] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [58] Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
• [59] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [60] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [61] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [62] Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
• [63] Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
• [64] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [65] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [66] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [67] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [68] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [69] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [70] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [71] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [72] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [73] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [74] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [75] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [76] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [77] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [78] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [79] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [80] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [81] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [82] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [83] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [84] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [85] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [86] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [87] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [88] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [89] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [90] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
• [91] In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
• [92] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [93] JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
• [94] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [95] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [96] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [97] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [98] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [99] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [100] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [101] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [102] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [103] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [104] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [105] Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
• [106] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [107] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [108] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [109] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [110] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [111] Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
• [112] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [113] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [114] Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
• [115] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [116] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [117] CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
• [118] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [119] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [120] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [121] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [122] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [123] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [124] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [125] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [126] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [127] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [128] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [129] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [130] Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol. 2002 Feb 1;436(1-2):7-13. doi: 10.1016/s0014-2999(01)01577-1.
• [131] Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells. Exp Cell Res. 2004 Jul 1;297(1):68-81. doi: 10.1016/j.yexcr.2004.02.017.
• [132] [P27(Kip1), cyclin E and endogenous TGF-beta1 changes in apoptosis of NB4 cells induced by As(2)O(3) and/or TGF-beta1 and their significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):74-9.
• [133] Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence. Int J Biochem Cell Biol. 2003 Feb;35(2):246-54. doi: 10.1016/s1357-2725(02)00129-2.
• [134] Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
• [135] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [136] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [137] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [138] Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
• [139] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
• [140] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [141] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [142] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [143] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [144] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [145] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [146] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [147] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [148] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [149] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [150] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [151] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [152] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [153] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [154] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [155] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [156] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [157] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [158] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [159] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [160] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [161] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [162] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [163] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [164] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [165] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [166] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [167] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [168] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [169] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [170] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [171] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [172] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [173] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [174] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [175] A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate. Cancer Gene Ther. 2008 Sep;15(9):576-90. doi: 10.1038/cgt.2008.28. Epub 2008 May 16.
• [176] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [177] Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J. 2001 Nov 1;359(Pt 3):537-46. doi: 10.1042/0264-6021:3590537.
• [178] Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl). 2002 Feb;115(2):280-5.
• [179] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [180] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [181] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [182] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [183] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [184] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [185] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
• [186] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [187] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [188] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [189] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [190] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [191] Benzo[a]pyrene increases the Nrf2 content by downregulating the Keap1 message. Toxicol Sci. 2010 Aug;116(2):549-61.
• [192] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [193] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [194] Cellular zinc homeostasis is a regulator in monocyte differentiation of HL-60 cells by 1 alpha,25-dihydroxyvitamin D3. J Leukoc Biol. 2010 May;87(5):833-44. doi: 10.1189/jlb.0409241. Epub 2010 Jan 20.
• [195] Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med. 2008 Sep 15;45(6):763-72.
• [196] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [197] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [198] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [199] RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis. 2004 Sep;9(5):561-71. doi: 10.1023/B:APPT.0000038030.47068.49.
• [200] Gallic acid protects against ethanol-induced hepatocyte necroptosis via an NRF2-dependent mechanism. Toxicol In Vitro. 2019 Jun;57:226-232. doi: 10.1016/j.tiv.2019.03.008. Epub 2019 Mar 7.
• [201] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [202] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [203] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [204] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [205] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [206] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [207] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [208] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [209] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [210] Systematic transcriptome-based comparison of cellular adaptive stress response activation networks in hepatic stem cell-derived progeny and primary human hepatocytes. Toxicol In Vitro. 2021 Jun;73:105107. doi: 10.1016/j.tiv.2021.105107. Epub 2021 Feb 3.
• [211] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [212] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [213] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [214] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [215] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [216] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [217] The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.
• [218] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [219] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [220] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [221] Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
• [222] Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: An in vitro study. Environ Toxicol. 2020 Nov;35(11):1179-1193. doi: 10.1002/tox.22983. Epub 2020 Jun 12.
• [223] Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology. 2001 Sep 14;166(1-2):79-89. doi: 10.1016/s0300-483x(01)00437-1.
• [224] Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J. 2006 Jul;20(9):1552-4. doi: 10.1096/fj.05-5413fje. Epub 2006 May 23.
• [225] Comparison of relative binding affinities to fish and mammalian estrogen receptors: the regulatory implications. Toxicol Lett. 2010 Feb 15;192(3):298-315. doi: 10.1016/j.toxlet.2009.11.004. Epub 2009 Nov 12.
• [226] Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ Health Perspect. 2004 Apr;112(5):524-31. doi: 10.1289/ehp.6649.
• [227] Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner. Reprod Toxicol. 2013 Dec;42:49-57. doi: 10.1016/j.reprotox.2013.07.019. Epub 2013 Jul 26.
• [228] Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci Biotechnol Biochem. 2002 Jul;66(7):1479-87. doi: 10.1271/bbb.66.1479.
• [229] Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. J Med Chem. 2011 Jan 13;54(1):302-11. doi: 10.1021/jm101163m. Epub 2010 Dec 3.
• [230] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [231] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [232] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [233] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [234] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [235] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [236] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [237] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [238] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [239] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [240] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [241] Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar 1;29(7):797-804. doi: 10.1200/JCO.2010.28.0792. Epub 2011 Jan 18.
• [242] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [243] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [244] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [245] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [246] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [247] Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.
• [248] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [249] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [250] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [251] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [252] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [253] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [254] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [255] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [256] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [257] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [258] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [259] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [260] Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett. 2015 Jun 15;235(3):189-98. doi: 10.1016/j.toxlet.2015.04.005. Epub 2015 Apr 9.
• [261] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [262] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [263] Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
• [264] Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
• [265] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [266] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [267] Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
• [268] Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.